A carregar...

Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective

Lenalidomide, a novel immunomodulatory agent, was approved by the US Food and Drug Administration for the treatment of myelodysplastic syndrome and relapsed multiple myeloma. Data from preclinical studies paved the way for clinical trials of lenalidomide in mantle cell lymphoma (MCL). Initial phase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Desai, Madhav, Newberry, Kate, Ou, Zhishuo, Wang, Michael, Zhang, Liang
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4031905/
https://ncbi.nlm.nih.gov/pubmed/24883181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620714532124
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!